Humoral theory of transplantation: some hot topics

Author： Cai Junchao Qing Xin Tan Jianming Terasaki Paul I.

ISSN： 1471-8391

Source： British Medical Bulletin, Vol.105, Iss.1, 2013-03, pp. : 139-155

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

IntroductionAntibody is a major cause of allograft injury. However, it has not been routinely tested post-transplant.Sources of dataA literature search was performed using PubMed on the topics of `antibody monitoring', `autoantibody and allograft dysfunction' and `prevention and treatment of antibody-mediated rejection (AMR)'.Areas of agreementDonor-specific antibody (DSA) monitoring not only helps to identify patients at risk of AMR, but also serves as a biomarker to personalize patient's maintenance immunosuppression. Development of autoantibody is a secondary response following primary tissue injury. Some autoantibodies are directly involved in allograft injury, while others only serve as biomarkers of tissue injury.Areas of controversyIt remains controversial whether DSA-positive patients without symptoms need to be treated. In addition, given the variation in study designs and patient's characteristics, there is discrepancy regarding which treatment regimens provide optimal clinical outcome in preventing/treating AMR.Growing pointsEfficacy of B-cell and/or antibody-targeted therapies in treating or preventing AMR would be better measured by the incorporation of antibody monitoring into current functional and pathological assays.Areas timely for developing researchResearch in B-cell targeted therapies to prevent and treat AMR is rapidly growing, which includes monoclonal antibodies against B-cell markers CD20, CD40, CD19, BlyS, etc. It requires extensive clinical research to determine the best approach to inhibit or delete antibody and how to balance the drug efficacy with safety.